Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Ascites
Interventions: Sodium restriction; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Hypertension
Interventions: PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: San Francisco, California • New York, New York

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension, Pulmonary, Hemolysis
Interventions: Nitric Oxide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions: Lifestyle Medicine Program, Medically Tailored Groceries; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Hypertension
Interventions: Remote Monitoring, Remote Monitoring + Social Support; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Gustavo A Heresi, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee

Conditions: Renal Insufficiency, Chronic Hypertension
Interventions: Spironolactone, Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 19 Years to 110 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 63
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 58 more

Conditions: Hypertension
Interventions: Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: High blood pressure treatment; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, Portal, Liver Cirrhosis
Interventions: Placebo, Avenciguat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Pasadena, California • Rialto, California

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Paradise Ultrasound Renal Denervation Treatment; Device
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 39 more

Conditions: Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions: Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiomyopathy, Cardiac Arrhythmia, Heart Failure, Chronic Thromboembolic Pulmonary Hypertension
Interventions: RF Assure Scanning; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypercholesterolaemia
Interventions: QCZ484, Inclisiran, QCZ484 placebo, Inclisiran placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Foley, Alabama • Saraland, Alabama • Lincoln, California + 24 more

Conditions: Hypertension
Interventions: Chart review; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Osteoarthritis, Controlled Hypertension
Interventions: lumiracoxib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,020 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: O'Fallon, Illinois

Conditions: Hypertension
Interventions: SPP100; Drug
Lead sponsor: LXO Group; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 11
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Dalton, Georgia + 7 more

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Osteoarthritis, Hypertension
Interventions: naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 29
States / cities: Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hypertension, Colon Cancer
Interventions: MINT, Patient Navigation; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older · Male only
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Sodium Restriction in the Management of Cirrhotic Ascites

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Remote Monitoring and Social Support for Hypertension Management

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Global Paradise System US Post Approval Study

Severe Sepsis in Children - IMPRESS-C

RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

Hypertension in Long-Term Care Facilities

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

Furosemide vs. Placebo for Severe Antepartum Hypertension

Community-based Approaches to Treating Hypertension and Colon Cancer Prevention